miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 17, 2025

NORWEGIAN CRUISE LINE® UNVEILS SUN-SOAKED WINTER 2027/28 DEPLOYMENT AND BRINGS BACK FREE AT SEA PLUS™ BY POPULAR DEMAND DELIVERING PREMIUM OFFERINGS

View original at finance.yahoo.com
NORWEGIAN CRUISE LINE® UNVEILS SUN-SOAKED WINTER 2027/28 DEPLOYMENT AND BRINGS BACK FREE AT SEA PLUS™ BY POPULAR DEMAND DELIVERING PREMIUM OFFERINGS - New Season of Sailings Features Over 370 Voyages Across Nearly 50 Countries, Including Two Prima Class Ships in San Juan, Expanded Caribbean Adventures as well as Once-i…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With longer port stays, overnight calls, and our award-winning onboard experiences, guests can explore at their own pace and personalize every moment at ease

    80% confidence

  • We're thrilled to unveil our new immersive winter season, giving travelers the ultimate freedom to create their own adventure

    80% confidence

  • With the return of Free at Sea Plus, guests will enjoy even greater value and convenience, making it easier than ever to relax and focus on what truly matters – reconnecting with those who matter most

    80% confidence

  • Many of our Bahamas and Caribbean itineraries will visit our exclusive private island destination, Great Stirrup Cay, which will feature a new pier, an oversized heated pool, and the Great Tides Waterpark

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com